Navigation Links
Stimulant treatment for ADHD not associated with increased risk of cardiac events in youth
Date:2/8/2012

Washington D.C., February 8, 2012 Attention-deficit/hyperactivity disorder (ADHD) affects 5-9% of youth and is frequently treated with stimulant medications, such as methylphenidate and amphetamine products. A recent safety communication from the US Food and Drug Administration advised that all patients undergoing ADHD treatment be monitored for changes in heart rate or blood pressure.

Amidst growing concern over the risks of stimulant use in youth, a study by Dr. Mark Olfson of the New York State Psychiatric Institute and Columbia University, and his colleagues, published in the February 2012 issue of the Journal of the American Academy of Child and Adolescent Psychiatry, assessed the risk of adverse cardiovascular events in children and adolescents without known heart conditions treated with stimulants for ADHD. It is one of the largest studies to date focusing primarily on youth while controlling for pre-existing cardiovascular risk factors.

As reported in the study, Olfson and colleagues examined claims records from a large privately insured population for associations between cardiovascular events in youth with ADHD and stimulant treatment. In total 171,126 privately insured youth aged 6-21 years without known pre-existing heart-related risk factors were followed throughout the study.

The study included patients who have previously received stimulant treatment, patients currently receiving stimulant treatment, and patients who began or ceased stimulant treatments during the study period. Olfson and colleagues assessed the various groups for incidents of severe cardiovascular events such as acute myocardial infarction, less severe cardiovascular events such as cardiac dysrhythmias, and cardiovascular symptoms such as tachycardia and palpitations. Analysis showed that cardiovascular events and symptoms were rare in this cohort and not associated with stimulant use.

This finding helps to allay concerns of adverse events in otherwise healthy young people receiving treatment for ADHD. Olfson and colleagues said of the results, "It is reassuring that in these young people, short-term stimulant treatment did not substantially increase the risk of cardiovascular events or symptoms."


'/>"/>

Contact: Mary Billingsley
Biol.Psych@utsouthwestern.edu
202-966-7300 x105
Elsevier
Source:Eurekalert

Related biology news :

1. Cancer Research Institute invests $450k in Oncovir to manufacture powerful immune stimulant
2. Breast cancer treatment resistance linked to signaling pathway
3. The dietary supplement genistein can undermine breast cancer treatment
4. Coming soon: Self-guided, computer-based depression treatment
5. Nanodiamond drug device could transform cancer treatment
6. Disinfectants can make bacteria resistant to treatment
7. Scientists from Granada find a potential treatment to prevent diabetes and obesity
8. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
9. Researchers at National Jewish Health evaluating a treatment
10. National Jewish Health researchers evaluating treatment to help emphysema sufferers breathe easier
11. First comprehensive genomic study of common cold reveals new treatment targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... Dec. 14, 2016 "Increase in mobile transactions ... The mobile biometrics market is expected to grow from ... by 2022, at a CAGR of 29.3% between 2016 ... as the growing demand for smart devices, government initiatives, ... "Software component is expected to grow at a ...
(Date:12/8/2016)... , Dec. 8, 2016  Singulex, Inc., the ... Counting technology, entered into a license and supply agreement ... science. The agreement provides Singulex access to Thermo Scientific ... Europe is used to diagnose systemic bacterial ... States to aid in assessing the risk ...
(Date:12/7/2016)... 2016   Avanade is helping Williams Martini ... in history, exploit biometric data in order to critically ... the competitive edge against their rivals after their impressive, ... Avanade has worked with Williams during the 2016 season ... (heart rate, breathing rate, temperature and peak acceleration) for ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... --  Boston Biomedical , an industry leader in the ... pathways, will feature data from two clinical studies for ... Gastrointestinal Cancers Symposium, held from January 19-21, in ... is an orally-administered investigational agent designed to inhibit cancer ... cells (CSCs) possess the property of stemness – the ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... Ops Executives 2017 in its continued commitment to the advancement of the clinical ... discuss current issues related to clinical trial planning and management. , As ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... federally funded bio-focused Manufacturing Innovation Institutes (MII). U.S. Secretary of Commerce Penny Pritzker ... Biopharmaceuticals (NIIMBL), and the Department of Defense has announced the award of a ...
(Date:1/18/2017)... PRUSSIA, PA (PRWEB) , ... January 18, 2017 ... ... clinical operations again at the CHI SCOPE Summit for Clinical Ops Executives (Hyatt ... in engaging panel discussions to examine vital clinical research issues such as trial ...
Breaking Biology Technology: